Tools for Practice Outils pour la pratique


#225 Topical Capsaicin for Neuropathic and Osteoarthritis Pain: Maybe not so hot?


CLINICAL QUESTION
QUESTION CLINIQUE
What are the benefits and harms of topical capsaicin for neuropathic or osteoarthritis pain?


BOTTOM LINE
RÉSULTAT FINAL
Evidence for topical capsaicin in neuropathic pain and hand osteoarthritis is highly inconsistent, with some studies showing clinical benefit (variably defined) for one in 4-7 patients while other studies show no benefit. There is no benefit in knee osteoarthritis. Local adverse effects (burning, stinging) in up to 60% of patients lead to one in 8-9 more stopping therapy.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
Neuropathic pain: 
  • Systematic review [seven Randomized Controlled Trials (RCTs), 1,600 patients, varied neuropathic pain types], 0.075% topical capsaicin versus placebo, 6-12 weeks:1 
    • Clinical improvement (variably defined): 42% versus 28% (placebo), not statistically different. 
    • Adverse events: 
      • Burning, stinging, or erythema: 63% versus 24% (placebo), Number Needed to Harm (NNH)=3. 
      • Coughing, sneezing: 9% versus 1% (placebo)NNH=13. 
      • Withdrawal: 15% versus 3% (placebo), NNH=9. 
  • Two other systematic reviews, 0.075% capsaicin versus placebo, at 4-8 weeks:2,3 
    • Benefit:  
      • Physician-rated “Much Better” (four RCTs, 309 patients):2 73% versus 49%, Number Needed to Treat (NNT)=5. 
      • ≥50% pain improvement (10 RCTs, 969 patients):3 NNT~7. 
    • Adverse events:3 
      • Local reaction: 58% versus 18%, NNH=3. 
      • Withdrawal: 16% versus 2%, NNH=8. 
  • RCT of 33 diabetic neuropathy patients,4 0.025% gel versus placebo: 
    • Pain score or patients achieving 30% pain reduction: No difference. 
    • Adverse skin reaction: 15% versus 0% (placebo), NNH=6. 
Osteoarthritis pain:  
  • Two systematic reviews (3-4 RCTs, 301-382 patients, hand osteoarthritis), 0.025%-0.075% topical capsaicin versus placebo at 4-8 weeks:2,5 
    • Clinical improvement, variably defined:2 45% versus 16%, NNT=4. 
    • Pain score ~8/100 points lower than placebo.5  
    • Adverse events not reported.2   
  • RCT (99 patients, knee osteoarthritis), 0.0125% capsaicin versus placebo over four weeks:6 No improvement. 
Limitations: Blinding likely compromised due to burning and redness.  Context: 
  • Burning or stinging usually receeds after several days of use.7 
  • 60-gram tube of 0.075% Capsaicin cream costs ~$30 (about 60-day supply based on QID use, depending on area). 
  • NICE recommends for localized neuropathic pain when oral medications not tolerated8 and as an add-on therapy for knee or hand osteoarthritis pain.9  


Latest Tools for Practice
Derniers outils pour la pratique

#365 Shrooms for Glooms: Evidence for psilocybin for depression

What are the benefits and harms of psilocybin for treatment-resistant/recurrent depression?
Read Lire 0.25 credits available Crédits disponibles

#364 Facing the Evidence in Acne, Part II: Oral Antibiotics

How effective are oral antibiotics in treating acne of at least mild-moderate severity?
Read Lire 0.25 credits available Crédits disponibles

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Danielle Perry BScN RN
  • G. Michael Allan MD CCFP

1. Derry S, Moore RA. Cochrane Database Syst Rev. 2012; (9):CD010111.

2. Zhang WY, Li Wan Po A. Eur J Clin Pharmacol. 1994; 46(6):517-22.

3. Mason L, Moore RA, Derry S, et al. BMJ. 2004; 328(7446):991.

4. Kulkantrakorn K, Lorsuwansiri C, Meesawatsom P. Pain Pract. 2013; (6):497-503.

5. Cameron M, Gagnier JJ, Little CV, et al. Phytother Res. 2009;(11):1497-515.

6. Cameron M, Chrubasik S. Cochrane Database Syst Rev. 2013; (5):CD010538.

7. CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2018 [updated 2018 July]. Capsaicin [product monograph] Available from: http://www.e-cps.ca or http://www.myrxtx.ca. Last Accessed: July 7, 2018.

8. National Institute for Health and Care Excellence. NICE Guideline (CG173). Available from: https://www.nice.org.uk/guidance/cg173. Last Accessed: June 27, 2018.

9. National Institute for Health and Care Excellence. NICE Guideline (CG177). Available from: https://www.nice.org.uk/guidance/cg177. Last Accessed: July 9, 2018.

Authors do not have any conflicts of interest to declare.

Les auteurs n’ont aucun conflit d’intérêts à déclarer.